ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.

S. Chadban,1 H. Pilmore,2 G. Russ,3 J. Kanellis,4 S. Campbell,5 P. O'Connell,6 W. Lim,7 M. Lutherborrow,8 N. Kurstjens,8 R. Walker.9

1Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia
2Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand
3Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia
4Renal Medicine, Monash Medical Centre, Melbourne, Australia
5University of Queensland, Princess Alexandra Hospital, Queensland, Australia
6Renal Medicine, Westmead Hospital, Sydney, Australia
7WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia
8Novartis Pharmaceuticals, Sydney, Australia
9Renal Medicine, Alfred Hospital, Melbourne, Australia.

Meeting: 2016 American Transplant Congress

Abstract number: 287

Keywords: Graft survival, Immunosuppression, Kidney transplantation, Malignancy

Session Information

Date: Monday, June 13, 2016

Session Name: Concurrent Session: Belatacept and Steroid Withdrawal in Kidney Transplantation

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:18pm-5:30pm

Location: Ballroom A

Related Abstracts
  • Treatment With Everolimus and Reduced-Exposure Cyclosporine Is Efficacious in De Novo Renal Transplant Recipients at Increased Risk for Efficacy Failure: Post-Hoc Analysis from the A2309 Study
  • Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients

A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine (EVR1.5), 3.0mg everolimus plus low exposure cyclosporine (EVR3.0) or 1.44g mycophenolic acid plus standard cyclosporine (MPA).

7-year data for 95 ANZ A2309 participants were extracted from the ANZDATA registry. Associations between treatment and outcomes, including rejection, eGFR, graft loss, death and cancer incidence were examined using adjusted generalized linear regression or Cox regression analyses by ITT analysis. Adverse events and discontinuation of study drugs (up to 2-years) were compared between treatment groups using data from Novartis.

Randomized to EVR1.5 or EVR3.0 were 66 (75.2%) recipients and to MPA 29 (24.8%. Compared to MPA, everolimus treatment was associated with adjusted hazards of 0.34 (95%CI 0.13, 0.91), 0.35 (0.09, 1.25) and 0.32 (0.15, 0.71) for non-melanoma skin cancers (NMSC), non-skin cancers and any cancers respectively, independent of age and waiting time. There was no association between treatment groups and graft function, rejection, graft loss or death up to 7-years after transplant. The adjusted mean (95%) difference in eGFR at 2 and 5-years were numerically (but not statistically significant) higher in the EVR1.5 group compared to MPA group (2 years: 8.66, 95%CI 1.46, 15.85; and 5 years: 4.68, 95%CI -5.37, 14.7mL/min/1.73m2). Adverse events and discontinuation rates were similar between treatment groups.

Compared to MPA, treatment with EVR was associated with > 50% reduction in cancer incidence, particularly NMSC. This data supports a class-effect for mTORi in reducing the burden of cancer after transplantation.

CITATION INFORMATION: Chadban S, Pilmore H, Russ G, Kanellis J, Campbell S, O'Connell P, Lim W, Lutherborrow M, Kurstjens N, Walker R. Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chadban S, Pilmore H, Russ G, Kanellis J, Campbell S, O'Connell P, Lim W, Lutherborrow M, Kurstjens N, Walker R. Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/everolimus-plus-reduced-exposure-cyclosporin-versus-mycophenolic-acid-plus-cyclosporin-seven-year-follow-up-of-australia-and-new-zealand-kidney-transplant-recipients-in-the-a2309-study/. Accessed March 3, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.